141 related articles for article (PubMed ID: 35938799)
1. Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
Yun HY; Chang MJ; Jung H; Chang V; Wang Q; Strydom N; Yoon YR; Savic RM
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0189321. PubMed ID: 35938799
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
4. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.
Al-Shaer MH; Märtson AG; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Houpt ER; Ashkin D; Griffith DE; Cegielski JP; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631828
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
Chirehwa MT; Resendiz-Galvan JE; Court R; De Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Warren R; Maartens G; Denti P; McIlleron H
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0142622. PubMed ID: 36744891
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients.
Shao G; Bao Z; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
Front Pharmacol; 2023; 14():1022090. PubMed ID: 37050904
[No Abstract] [Full Text] [Related]
10. Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis.
Hsu HL; Bai KJ; Chiang YC; Lin SJ; Yu MC
J Formos Med Assoc; 2010 Dec; 109(12):923-7. PubMed ID: 21195892
[TBL] [Abstract][Full Text] [Related]
11. Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
Jiang H; Li X; Xing Z; Niu Q; Xu J
Curr Drug Deliv; 2023; 20(3):306-316. PubMed ID: 35546770
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea.
Jeong HE; Choi J; Oh IS; Son H; Jang SH; Jung SY; Shin JY
J Microbiol Immunol Infect; 2022 Oct; 55(5):917-925. PubMed ID: 34896029
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis.
Lee HW; Kim DW; Park JH; Kim SD; Lim MS; Phapale PB; Kim EH; Park SK; Yoon YR
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1161-6. PubMed ID: 19723408
[TBL] [Abstract][Full Text] [Related]
15. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
[TBL] [Abstract][Full Text] [Related]
16. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
[TBL] [Abstract][Full Text] [Related]
17. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon.
Kuaban C; Noeske J; Rieder HL; Aït-Khaled N; Abena Foe JL; Trébucq A
Int J Tuberc Lung Dis; 2015 May; 19(5):517-24. PubMed ID: 25868018
[TBL] [Abstract][Full Text] [Related]
18. Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.
Lee SH; Seo KA; Lee YM; Lee HK; Kim JH; Shin C; Ghim JR; Shin JG; Kim DH
Yonsei Med J; 2015 Jul; 56(4):961-7. PubMed ID: 26069117
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.
Zhang H; He Y; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Alffenaar JW; Hu Y
Front Pharmacol; 2022; 13():1032674. PubMed ID: 36699070
[No Abstract] [Full Text] [Related]
[Next] [New Search]
